BMS sues over generic of blockbuster leukaemia treatment

Bristol-Myers Squibb (BMS) has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel (dasatinib), infringes a pair of patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

18 January 2022 The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.

Generics

BMS sues MSN over Pomalyst generic

7 April 2022 Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

Generics

BMS says Hengrui’s Abraxane infringes

13 May 2022 A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.

More on this story

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

Generics

BMS sues MSN over Pomalyst generic

7 April 2022 Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

Generics

BMS says Hengrui’s Abraxane infringes

More on this story

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

Generics

BMS sues MSN over Pomalyst generic

7 April 2022 Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

Generics

BMS says Hengrui’s Abraxane infringes